Healthcare & Pharma

While almost all healthcare providers are now using EHR systems, the data and information stored in these systems is often very difficult to access by patients and healthcare providers across different settings of care. All the stakeholders in healthcare will immensely benefit from a fully connected healthcare system that empowers patients, caregivers, and their healthcare providers to access and use electronic health information (EHI). The digitization of the US Federal healthcare system has resulted in greater electronic citations of health information for patients. The Federal government is striving to increase transparency, protection of privacy, wider choice for patients and data security of patients’ Electronic health Information.

As a company providing IT Solutions to healthcare and pharmaceutical industry, Deosi LLC provides support to doctors and staff in their routine work. For this, we consistently develop innovations that focus on improving the health and well-being of the citizens. Our Solutions and services enhance the communication between the healthcare providers and patients to improve the diagnosis process. Our mission is to offer solutions to expedite the healthcare process.

They are the primary way that researchers find out if a new treatment, like a new drug or diet or medical device is safe and effective in people.

• Phase: Primary goal
• Phase I: Dose-ranging on healthy volunteers for safety
• Phase II: Testing of drug on participants to assess efficacy and side effects
• Phase III: Testing of drug on participants to assess efficacy, effectiveness and safety
• Phase IV: Post marketing surveillance in public

This platform enables eConsent , notification and alerts , ECOA, data collection and data capture and reporting dashboards. Some of the features of this mobile platform are as below: 

1. Digitally qualify patients by defining a series of questions to determine whether a patient qualifies to participate in a clinical trial. 
2. eConsent tackles the multi-page informed consent by delivering information in shorter segments that are easier to understand. 
3. Quickly incorporate identity verification and authentication using two-factor authentication to ensure the identity of each patient prior to digitally signing the eConsent form.
4. Comprehension check helps the clinical operations team determine if a patient fully understands or if they are in need of additional information.

The terminologies used for Clinical Trials are as follows:

• Patient diary: It is a tool used to collect subjective data from a patient, including conditions, symptoms and other measures.
• Electronic patient diary (eDiary): Electronically registers data of the patient and automates data entries on a handheld mobile device, tablet or computer
• Clinical outcome assessment (COA): COA is used to measure and evaluate patient safety and quality of life. These include:
  • Patient-reported outcome (PRO): Health outcome reported directly by the patient
  • Performance outcome (PerfO): Measurement based on the tasks performed by a patient according to instructions given by a care staff.
  • Clinician-reported outcome (ClinRo): Using their clinical judgment, caregivers or other site staff report patient health outcomes after observing the patient’s health condition
  • Observer reported outcomes (ObsRo): These are the outcomes reported by the patient’s family members or other observer.
• Electronic clinical outcome assessment (eCOA): The eCOA makes use of technologies such as tablets, handheld devices or web to allow caregivers, patients and clinicians to directly report outcomes, resulting in granular endpoint data and information. 

This will also enable convenient on- demand access by diverse nationwide user population which will also include the patients, healthcare providers and clinical investigators.

The synergistic effects between experimental and data computational approaches on the assortment and optimization of bioactive compounds emphasize the importance of the integration of advanced technologies in drug discovery programs. These technologies (VS, HTS, SBDD, LBDD and QSAR) are harmonizing in the sense that they have common goals; thereby the combination of both empirical and in-silo efforts is feasible at many different levels of lead optimization and new chemical entity (NCE) discovery.

Data migration may also take place within systems built on HDD or SDD, or between in-house systems and cloud storage.